Long-term denosumab treatment restores cortical bone loss and reduces fracture risk at the forearm and humerus: analyses from the FREEDOM Extension cross-over group.


Journal

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
ISSN: 1433-2965
Titre abrégé: Osteoporos Int
Pays: England
ID NLM: 9100105

Informations de publication

Date de publication:
Sep 2019
Historique:
received: 20 07 2018
accepted: 15 05 2019
pubmed: 16 6 2019
medline: 11 2 2020
entrez: 16 6 2019
Statut: ppublish

Résumé

Upper limb fractures (including wrist, forearm, and humerus) represent a significant burden among postmenopausal women with osteoporosis. Up to 7 years of treatment with denosumab resulted in an increase in bone mineral density and decrease in fractures in upper limb sites. Upper limb (wrist, forearm, and humerus) fractures are a significant burden in osteoporosis, associated with significant morbidity and mortality. Denosumab, a monoclonal antibody against RANK ligand, increases bone mineral density (BMD) and decreases vertebral, nonvertebral, and hip fractures. Here, we evaluated the long-term effect of denosumab treatment on upper limb fracture risk and BMD. In the FREEDOM trial, subjects were randomized 1:1 to receive every-6-month denosumab 60 mg or placebo subcutaneously for 3 years, after which all subjects could receive denosumab for up to 7 years (Extension). Among placebo subjects who completed FREEDOM and enrolled in the Extension, wrist, forearm, humerus, and upper limb fracture rates and rate ratios between different time periods (FREEDOM years 1-3, Extension years 1-3, and Extension years 4-7) were computed. BMD at the ultradistal radius, 1/3 radius, and total radius was analyzed in a subset of subjects in a BMD substudy. This analysis included 2207 subjects (116 in the BMD substudy). Fracture rates decreased over the 7-year Extension; fracture rate ratios between Extension years 4-7 (denosumab) and FREEDOM years 1-3 (placebo) reduced significantly for the wrist (0.57), forearm (0.57), humerus (0.42), and upper limb (0.52; p < 0.05 for all). Percentage increase in BMD from Extension baseline at the ultradistal radius, 1/3 radius, and total radius was significant by Extension year 7 (p < 0.05 for all). Long-term treatment with denosumab decreases upper limb fracture risk and increases forearm BMD, suggesting beneficial effects on both cortical and trabecular bone accruing over time.

Identifiants

pubmed: 31201481
doi: 10.1007/s00198-019-05020-8
pii: 10.1007/s00198-019-05020-8
pmc: PMC6719332
doi:

Substances chimiques

Bone Density Conservation Agents 0
Denosumab 4EQZ6YO2HI

Types de publication

Clinical Trial, Phase III Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

1855-1864

Références

Lancet. 1999 Mar 13;353(9156):878-82
pubmed: 10093980
Osteoporos Int. 1999;9(6):469-75
pubmed: 10624452
J Clin Endocrinol Metab. 2000 Apr;85(4):1492-7
pubmed: 10770187
J Bone Miner Res. 2000 Apr;15(4):721-39
pubmed: 10780864
J Clin Endocrinol Metab. 2000 Nov;85(11):4118-24
pubmed: 11095442
Am J Epidemiol. 2001 Mar 15;153(6):587-95
pubmed: 11257067
N Engl J Med. 2001 May 10;344(19):1434-41
pubmed: 11346808
Arch Intern Med. 2004 May 24;164(10):1108-12
pubmed: 15159268
J Bone Miner Res. 2005 Feb;20(2):185-94
pubmed: 15647811
Osteoporos Int. 2006 Dec;17(12):1726-33
pubmed: 16983459
JAMA. 2006 Dec 27;296(24):2927-38
pubmed: 17190893
Pharmacotherapy. 2007 Jun;27(6):779-88
pubmed: 17542760
Cochrane Database Syst Rev. 2008 Jan 23;(1):CD001155
pubmed: 18253985
J Bone Miner Res. 2009 Jan;24(1):153-61
pubmed: 18767928
J Bone Miner Res. 2010 Jan;25(1):72-81
pubmed: 19594293
N Engl J Med. 2009 Aug 20;361(8):756-65
pubmed: 19671655
J Bone Miner Res. 2010 Aug;25(8):1886-94
pubmed: 20222106
Bone. 2010 Jul;47(1):131-9
pubmed: 20399288
Bone. 2011 Apr 1;48(4):677-92
pubmed: 21145999
Osteoporos Int. 2011 Sep;22(9):2439-48
pubmed: 21161507
J Clin Densitom. 2013 Apr-Jun;16(2):147-53
pubmed: 22521543
Menopause. 2013 Feb;20(2):130-7
pubmed: 23010883
Osteoporos Int. 2013 Mar;24(3):811-23
pubmed: 23306819
Bone. 2014 Feb;59:173-9
pubmed: 24275677
Osteoporos Int. 2014 May;25(5):1439-43
pubmed: 24577348
J Bone Miner Res. 2015 May;30(5):934-44
pubmed: 25545380
Osteoporos Int. 2015 Dec;26(12):2763-71
pubmed: 26068295
J Clin Endocrinol Metab. 2016 Aug;101(8):3163-70
pubmed: 27270237
Ther Adv Musculoskelet Dis. 2016 Dec;8(6):225-235
pubmed: 28255336
Lancet Diabetes Endocrinol. 2017 Jul;5(7):513-523
pubmed: 28546097
Ann Chir Gynaecol. 1988;77(1):27-31
pubmed: 3207343
N Engl J Med. 1995 Mar 23;332(12):767-73
pubmed: 7862179
Calcif Tissue Int. 1993 Apr;52(4):269-72
pubmed: 8467406
Osteoporos Int. 1993 May;3(3):133-7
pubmed: 8481589
Lancet. 1996 Dec 7;348(9041):1535-41
pubmed: 8950879
JAMA. 1998 Dec 23-30;280(24):2077-82
pubmed: 9875874

Auteurs

J P Bilezikian (JP)

College of Physicians and Surgeons, Columbia University, New York, NY, USA. jpb2@cumc.columbia.edu.

C J F Lin (CJF)

Amgen Inc., Thousand Oaks, CA, USA.

J P Brown (JP)

CHU de Québec Research Centre and Laval University, Quebec City, QC, Canada.

A T Wang (AT)

Amgen Inc., Thousand Oaks, CA, USA.

X Yin (X)

Amgen Inc., Thousand Oaks, CA, USA.

P R Ebeling (PR)

Department of Medicine, Monash University, Clayton, Australia.

A Fahrleitner-Pammer (A)

Medical University, Graz, Austria.

E Franek (E)

Mossakowski Medical Research Center, Polish Academy of Sciences, Warsaw, Poland.

N Gilchrist (N)

The Burwood Hospital, Christchurch, New Zealand.

P D Miller (PD)

Colorado Center for Bone Research, Golden, CO, USA.

J A Simon (JA)

George Washington University, Washington, DC, USA.

I Valter (I)

Center for Clinical and Basic Research, Tallinn, Estonia.

C A F Zerbini (CAF)

Centro Paulista de Investigação Clinica, São Paulo, Brazil.

C Libanati (C)

Amgen Inc., Thousand Oaks, CA, USA.

A Chines (A)

Amgen Inc., Thousand Oaks, CA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH